Advances in nano-based inner ear delivery systems for the treatment of sensorineural hearing loss

详细信息    查看全文

• 作者：Lilun Li^a ; ^b ; Tiffany Chao^a ; Jason Brant^a ; Bert O'Malley Jr.^a ; Andrew Tsourkas^c ; Daqing Li^a ; ^{lidaqing@mail.med.upenn.edu}
• 关键词：Nanomedicine ; Nanohydrogel ; Targeted delivery ; Ototoxicity ; Nanodialysis ; Inner ear
• 刊名：Advanced Drug Delivery Reviews
• 出版年：2017
• 出版时间：1 January 2017
• 年：2017
• 卷：108
• 期：Complete
• 页码：2-12
• 全文大小：1199 K
• 卷排序：108

文摘

Sensorineural hearing loss (SNHL) is one of the most common diseases, accounting for about 90% of all hearing loss. Leading causes of SNHL include advanced age, ototoxic medications, noise exposure, inherited and autoimmune disorders. Most of SNHL is irreversible and managed with hearing aids or cochlear implants. Although there is increased understanding of the molecular pathophysiology of SNHL, biologic treatment options are limited due to lack of noninvasive targeted delivery systems. Obstacles of targeted inner ear delivery include anatomic inaccessibility, biotherapeutic instability, and nonspecific delivery. Advances in nanotechnology may provide a solution to these barriers. Nanoparticles can stabilize and carry biomaterials across the round window membrane into the inner ear, and ligand bioconjugation onto nanoparticle surfaces allows for specific targeting. A newer technology, nanohydrogel, may offer noninvasive and sustained biotherapeutic delivery into specific inner ear cells. Nanohydrogel may be used for inner ear dialysis, a potential treatment for ototoxicity-induced SNHL.